Author: admin

Biodegradable Straws Market Size, Share, Industry Trends And Forecast 2024-2031

Explore the booming Biodegradable Straws Market, driven by eco-conscious shifts, government regulations, and innovative offerings, witnessing exponential growth until 2031.

Market Dynamics:

Environmental Shifts and Regulatory Impact:

The Biodegradable Straws Market has surged due to escalating environmental concerns and stringent regulations against plastic straw usage worldwide. Cities and nations globally are enacting laws banning plastic straws, compelling cafes and restaurants to adopt biodegradable alternatives. This shift towards sustainability is significantly boosting the market.

North American Initiatives and Start-Up Surge:

North America is at the forefront of this eco-friendly revolution, witnessing numerous regional and national initiatives promoting reduced single-use plastics. This has led to the emergence of startups capitalizing on the growing market. The Break Free From Plastic Pollution Act, ongoing since 2020, exemplifies the region’s commitment to curbing plastic usage.

Corporate Commitments and Sustainable Practices:

Global corporations, including Starbucks and McDonald’s, are making substantial commitments to eliminate plastic straws from their establishments. These efforts align with broader sustainability initiatives, prompting companies to opt for biodegradable straws. Marriott International and American Airlines are among those pledging to abandon single-use plastic straws.

Download Sample

Biodegradable Straws Market Segmentation Analysis:

Application in Household:

The demand for biodegradable paper straws, especially in households, is poised to dominate the market. Various types of paper straws, such as plain, printed, colored, and wrapped, cater to diverse applications like foodservice, retail, and household use. As countries ban single-use plastics, the popularity of paper straws is expected to soar.

 Key Players and Innovation:

Key players like Aardvark Straws, Hoffmaster Group, Huhtamaki Oyj, and The Paper Straw Co. focus on product innovation and sustainable sourcing. These companies strategically form partnerships to gain a competitive edge. The market thrives on continual innovation and a commitment to environmentally friendly practices.

Geographical Analysis:

Rising Environmental Concerns in North America:

North America is anticipated to be a dominant region in the Biodegradable Straws Market. Stringent environmental regulations and growing concerns have prompted government initiatives against single-use plastics, leading to bans in various states. The ongoing Break Free From Plastic Pollution Act underscores the region’s dedication to environmental stewardship.

Key Players:

Aardvark Straws, HAY! Straws, The Paper Straw Co., Hello Straw, Huhtamäki Oyj, The Blue Straw, BioPak Pty Ltd, Sulapac Oy, SAS OSTONE, AvoplastiQs LLC, Phade, WinCup, UrthPact, LLC, Eagle Beverage Products, AvoplastiQs LLC, and others.

Relevant Reports:

Variable Data Printing Labels Market 

Thermoforming Packaging Market 

Fiber based Packaging Market 

Media Contact
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Send Email
Phone: 08774414866
Address:DATAM INTELLIGENCE 4MARKET RESEARCH LLP Ground floor, DSL Abacus IT Park, Industrial Development Area, Uppal, Hyderabad, Telangana 500039
City: HYDERABAD
State: Telangana
Country: India
Website: https://www.datamintelligence.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Biodegradable Straws Market Size, Share, Industry Trends And Forecast 2024-2031

Radiodermatitis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Apeiron Biologics, Lutris Pharma Ltd., Reata Pharma, Lutris Pharma

“Radiodermatitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Radiodermatitis, historical and forecasted epidemiology as well as the Radiodermatitis market trends in the 7MM.

DelveInsight’s “Radiodermatitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Radiodermatitis, historical and forecasted epidemiology as well as the Radiodermatitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Radiodermatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Radiodermatitis Market Forecast

 

Some of the key facts of the Radiodermatitis Market Report: 

  • The Radiodermatitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In 7MM, there were almost 3,000 incidents of radiation dermatitis in 2022, with the US accounting for the majority of cases, or 1,300, followed by Japan
  • The most cases of radiotherapy utilisation in the US in 2022 were for breast cancer, followed by lung cancer and prostate cancer
  • The number of Radiation Dermatitis cases that were successfully treated in the US in 2022 was estimated to be 1,150 for patients receiving prophylaxis and 1,200 for patients receiving treatment
  • Germany had the most incident instances of radiation dermatitis among the EU4 countries, whereas Spain has the fewest
  • There were 644,000 cases of Grade II (moderate dermatitis) in the US in 2022.
  • Key Radiodermatitis Companies: Apeiron Biologics, Lutris Pharma Ltd., Reata Pharma, Lutris Pharma, Enveric Biosciences, Xequel Bio, and others
  • Key Radiodermatitis Therapies: APN201, LUT014 Gel, Omaveloxolone, LUT014, EV102, GrenexinGel, and others
  • The Radiodermatitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Radiodermatitis pipeline products will significantly revolutionize the Radiodermatitis market dynamics.

 

Radiodermatitis Overview

The word “radiodermatitis,” also known as “radiation dermatitis,” “x-ray dermatitis,” “radiation skin damage,” or “eradiation burn,” refers to a disorder that primarily affects the skin after receiving radiation therapy.

 

Get a Free sample for the Radiodermatitis Market Report:

https://www.delveinsight.com/report-store/radiodermatitis-market

 

Radiodermatitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Radiodermatitis Epidemiology Segmentation:

The Radiodermatitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Radiodermatitis
  • Prevalent Cases of Radiodermatitis by severity
  • Gender-specific Prevalence of Radiodermatitis
  • Diagnosed Cases of Episodic and Chronic Radiodermatitis

 

Download the report to understand which factors are driving Radiodermatitis epidemiology trends @ Radiodermatitis Epidemiology Forecast

 

Radiodermatitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Radiodermatitis market or expected to get launched during the study period. The analysis covers Radiodermatitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Radiodermatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Radiodermatitis Therapies and Key Companies

  • APN201: Apeiron Biologics
  • LUT014 Gel: Lutris Pharma Ltd.
  • Omaveloxolone: Reata Pharma
  • LUT014: Lutris Pharma
  • EV102: Enveric Biosciences
  • GrenexinGel: Xequel Bio

 

Discover more about therapies set to grab major Radiodermatitis market share @ Radiodermatitis Treatment Market

 

Scope of the Radiodermatitis Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Radiodermatitis Companies: Apeiron Biologics, Lutris Pharma Ltd., Reata Pharma, Lutris Pharma, Enveric Biosciences, Xequel Bio, and others
  • Key Radiodermatitis Therapies: APN201, LUT014 Gel, Omaveloxolone, LUT014, EV102, GrenexinGel, and others
  • Radiodermatitis Therapeutic Assessment: Radiodermatitis current marketed and Radiodermatitis emerging therapies
  • Radiodermatitis Market Dynamics: Radiodermatitis market drivers and Radiodermatitis market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Radiodermatitis Unmet Needs, KOL’s views, Analyst’s views, Radiodermatitis Market Access and Reimbursement 

 

To know more about Radiodermatitis companies working in the treatment market, visit @ Radiodermatitis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Radiodermatitis Market Report Introduction

2. Executive Summary for Radiodermatitis

3. SWOT analysis of Radiodermatitis

4. Radiodermatitis Patient Share (%) Overview at a Glance

5. Radiodermatitis Market Overview at a Glance

6. Radiodermatitis Disease Background and Overview

7. Radiodermatitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Radiodermatitis 

9. Radiodermatitis Current Treatment and Medical Practices

10. Radiodermatitis Unmet Needs

11. Radiodermatitis Emerging Therapies

12. Radiodermatitis Market Outlook

13. Country-Wise Radiodermatitis Market Analysis (2019–2032)

14. Radiodermatitis Market Access and Reimbursement of Therapies

15. Radiodermatitis Market Drivers

16. Radiodermatitis Market Barriers

17.  Radiodermatitis Appendix

18. Radiodermatitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Radiodermatitis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Apeiron Biologics, Lutris Pharma Ltd., Reata Pharma, Lutris Pharma

Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB

Ocugen Inc. (NASDAQ: OCGN) emerges as a noteworthy biotech stock for investors to monitor in upcoming trading sessions. On February 22, 2024, Ocugen Inc. reported the successful completion of the initial cohort in the Phase 1/2 GARDian clinical trial for its OCU410ST product. This product, a modifier gene therapy candidate, aims to address Stargardt disease, an orphan blindness condition affecting approximately 35,000 individuals solely in the United States. Dr. Arun Upadhyay, Ocugen’s Head of Research and Development and Chief Scientific Officer highlighted this achievement as a significant clinical milestone for the company. OCU410ST represents a pioneering, potentially one-time therapy for Stargardt disease sufferers. With a surge in after-hours trading on February 26, 2024, keeping a close watch on Ocugen’s stock performance could prove prudent. 

Venus Concept Inc. (NASDAQ: VERO), a leading global provider of medical aesthetic technology, revealed on February 23, 2024, that it had engaged in a registered direct offering, adhering to NASDAQ regulations regarding market pricing. Under this agreement, the company plans to offer 817,748 shares of its common stock at a price of $$1.465 per share. Simultaneously, Venus Concept Inc. will conduct a private placement, issuing unregistered warrants enabling the purchase of up to 817,748 shares of common stock at an exercise price of $1.34 per share. These warrants will be immediately exercisable upon issuance and will remain valid for a period of five years from the date of issuance. 

Redwood Scientific Technologies Inc. (OTC: RSCI) The company witnessed a remarkable uptick in its stock performance across a span of 5 trading sessions, achieving an impressive gain of 97.95%. Concurrently, the trading volume for the stock exhibited significant vigor. On February 6, 2024, it was revealed that Redwood Scientific Technologies Inc. had entered a partnership with Jeeva Clinical Trials. This collaboration is geared towards initiating clinical effectiveness studies for Redwood Scientific Technologies’ TBX-free oral strips, designed to aid in smoking and e-cigarette cessation efforts. 

Catheter Precision (NYSE American: VTAK), a leading technology firm specializing in state-of-the-art electrophysiology techniques for treating cardiac arrhythmias, introduced its LockeT suture closure device at the upcoming International Symposium on Left Atrial Appendage, scheduled for March 1-2, 2024, at the Intercontinental New York Times Square. This event is poised to draw worldwide attention and provide essential education for healthcare professionals in cardiology, electrophysiology, and internal medicine. Additionally, Catheter Precision Inc. showcased its latest innovations at the AF Symposium conference held from February 1-3, 2024, in Boston, Massachusetts. Catheter Precision Inc. (NYSE American: VTAK) gained recognition as a prominent innovator in the swiftly growing medical manufacturing sector, notably highlighted in a feature in “MedTech Outlook.” With a focus on electrophysiology (EP) technology, delve into the complete interview in “MedTech Outlook” for thorough insights, and also explore the EP Lab Digest Case Study. 

Enveric Biosciences (NASDAQ: ENVB) operates as a biotechnology company dedicated to advancing neuroplastogenic small-molecule therapeutics aimed at addressing conditions such as anxiety, depression, and addiction-related disorders. On February 23, 2024, Enveric Biosciences disclosed an arrangement to divest a specific cancer-focused patent portfolio, the financial terms of which were not disclosed. Despite this transaction, the company affirmed its commitment to advancing EB 003, its primary candidate, through ongoing investment and research efforts.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB

Robert Keenan of The Empire Publishers Named Amongst Top 50 Influential Figures in the Publishing Industry

Celebrating a Trailblazer in the Publishing Landscape Specializing in Emerging Voices in Literature

Texas, USA – February 28, 2024 – The Empire Publishers, a leading force in the global publishing domain, proudly announces the recognition of Robert Keenan, its Director of Marketing and Business Development, as one of the top 50 influential figures in the publishing industry. This accolade acknowledges his exceptional contributions to the company’s remarkable growth and influence within the publishing landscape.

Robert Keenan has played a pivotal role in driving growth and innovation at The Empire Publishers, leading various strategic initiatives that have propelled the company’s success. Under Keenan’s guidance, The Empire Publishers has achieved remarkable milestones, including expanded market presence, increased readership, and enhanced brand recognition.

In response to this achievement, Keenan expressed his gratitude, stating, “It’s an honor to be recognized among such distinguished individuals in the publishing sector. I attribute this accomplishment to the unwavering dedication and innovative spirit of our team at The Empire Publishers.”

Stephen Houser, CEO of The Empire Publishers, shared his perspective on this milestone, remarking, “Robert’s strategic vision and leadership have been instrumental in propelling Empire Publishing to new heights, solidifying our position as a powerhouse in the global publishing arena.”

The Empire Publishers team extends heartfelt congratulations to Robert Keenan for this well-deserved recognition, further reaffirming their commitment to continued excellence and innovation in the publishing industry.

As The Empire Publishers continue to innovate and redefine the publishing landscape, Keenan’s leadership will undoubtedly continue to inspire and drive the company’s forward momentum. Under his guidance, the publishing house is primed to sustain its upward momentum, enabling authors to amplify their narratives to broader audiences and leaving an enduring imprint on the literary realm.

Media Contact
Company Name: The Empire Publishers
Contact Person: Andreea Stan
Email: Send Email
Phone: (844) 636-4576
Address:12808 W Airport Blvd, 270M
City: Sugar Land
State: Texas 77478
Country: United States
Website: https://www.theempirepublishers.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Robert Keenan of The Empire Publishers Named Amongst Top 50 Influential Figures in the Publishing Industry

Embarc Advisors Lands on Inc. Magazine’s Fastest-Growing Private Companies List

Los Angeles, California – In a significant acknowledgment of its rapid growth and innovative business strategies, Embarc Advisors proudly announces its rank as number 21 out of 170 companies on the Inc. 5000 Regionals: Pacific list for 2024. This prestigious ranking by Inc. Magazine celebrates Embarc Advisors’ dedication to providing exceptional and innovative financial advisory services, particularly its groundbreaking hourly-fee based payment structure.

Founder and Principal Jay Jung remarked on the achievement, “I am grateful to our team members for achieving this recognition by Inc. Magazine. It validates our innovative approach to M&A and CFO advisory, demonstrating that there is opportunity to innovate and drive high growth even in the most crowded and established of service industries.”

Philip Alberstat, Managing Director, also commented, “This accolade is more than just a ranking for us; it’s a motivation to continue disrupting the financial advisory space. Our inclusion in the Inc. 5000 Regionals is a reflection of our commitment to excellence and a clear indication that our unique model is resonating with clients across the region.”

Embarc Advisors has distinguished itself in the corporate finance advisory sector with its client-focused strategies, particularly its hourly-fee based payment model, which offers a flexible and transparent alternative to traditional success-based transaction fee structures. This innovative solution has not only fueled Embarc Advisors’ growth but has also reinforced its reputation as a trusted partner to its diverse clientele.

Discover more about Embarc Advisors and how they revolutionize financial advisory services by visiting embarcadvisors.com. Explore their unique approach to financial advisory and learn about the industries they empower.

About Embarc Advisors

Embarc Advisors is building a disruptive corporate finance advisory firm focused on startups, and the middle-market. Founded by a former Goldman Sachs investment banker and McKinsey & Co. consultant, the company delivers the highest level of corporate finance advisory. Rejecting the traditional transaction-fee-based business, Embarc’s hourly rate-based fee model delivers a white-glove approach to select deal opportunities to drive above-market outcomes. Embarc’s unique business model allows it to support clients through the entire life cycle of the company from capital raise, strategic CFO services, outsourced corporate development and sale of the business.  

Composed of a seasoned group of corporate finance experts with backgrounds in investment banking, private equity, consulting, investment management, and strategic finance / FP&A, Embarc is uniquely positioned to provide 360-degree support on the full spectrum of corporate finance needs. Since its inception in 2020, the company successfully closed multiple M&A transactions, executed capital raises from early-stage seed to $100M+ growth equity rounds, and supported the sustainable, profitable growth of several companies as their strategic CFO team.

Media Contact
Company Name: Embarc Advisors
Contact Person: Caleb Harper
Email: Send Email
Country: United States
Website: https://embarcadvisors.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Embarc Advisors Lands on Inc. Magazine\’s Fastest-Growing Private Companies List

Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS

Lately, several companies have garnered attention for various reasons, and this article aims to delve into five of them, offering insights into their recent developments. 

Dyadic International Inc. (NASDAQ: DYAI) experienced significant movement in its stock last week, with trading volumes surpassing the average and reaching a six-month high. The company specializes in advanced microbial platforms for protein development and bioproduction to address clinical needs. On February 21, 2024, it was revealed that Dyadic extended its partnership with the Israel Institute for Biological Research (IIBR) and its affiliate, Life Sciences Research Israel (LSRI), to develop solutions for emerging diseases. Earlier in February 2024, Dyadic garnered attention for its partnership with Cygnus Technologies, a division of Maravai LifeSciences (NASDAQ: MRVI) and on Friday, February 23, 2024, Maravai LifeSciences (NASDAQ: MRVI) surged by 63.6%, gaining $3.25 to close at $8.36. 

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) made an announcement on February 22, 2024, regarding its definitive agreement to acquire the rights to GAVRETO in the United States from Blueprint Medicines Corporation. According to the press release, GAVRETO is an oral small-molecule kinase inhibitor targeting oncogenic RET fusions and wild-type RET fusions. GAVRETO has already received approval from the United States Food and Drug Administration for treating adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancer cases in the US, with RET fusions occurring in approximately 1-2% of the total patient population. 

Ardelyx Inc. (NASDAQ: ARDX) is a biopharmaceutical firm founded with the objective of developing, discovering, and commercializing pioneering medications to address unmet medical needs. On February 22, 2024, Ardelyx Inc. disclosed its financial outcomes for the fourth quarter and full fiscal year concluding on December 31, 2023. By December 31, 2023, the company possessed $184.3 million in cash, cash equivalents, and short-term investments. Total revenues for the fiscal year surged to $124.5 million from $52.2 million in the previous year, 2022. 

Venus Concept Inc. (NASDAQ: VERO), a leading global provider of medical aesthetic technology, revealed on February 23, 2024, that it had engaged in a registered direct offering, adhering to NASDAQ regulations regarding market pricing. Under this agreement, the company plans to offer 817,748 shares of its common stock at a price of $1.465 per share. Simultaneously, Venus Concept Inc. will conduct a private placement, issuing unregistered warrants enabling the purchase of up to 817,748 shares of common stock at an exercise price of $1.34 per share. These warrants will be immediately exercisable upon issuance and will remain valid for a period of five years from the date of issuance. 

TRxADE HEALTH INC. (NASDAQ: MEDS) serves as the parent entity of a B2B exchange platform catering to the pharmaceutical sector. On January 17, TRxADE HEALTH Inc. made public the submission of its quarterly report, Form 10-Q, for the quarter concluding on September 30, 2023. Notably, on November 21, 2023, the Nasdaq Listing Qualifications Department notified the company of its noncompliance due to the delayed filing of Form 10-Q. On February 20, 2024, TRxADE HEALTH’s stock witnessed a remarkable surge, climbing by 98.04% to reach an intraday peak of $10.68, eventually closing at $9.09 with a trading volume of 12.44 million shares. Presently, the stock is trading within an elevated range, surpassing its 10, 20, 50, and 200-day moving averages at $8.58 per share.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS

AV Access Launches New Dual Monitor KVM Extender for Enhanced Home Office and Gaming Experience

“Nowadays, more people working from home tend to place their host PCs in an equipment room and control them remotely with two monitors and a set of USB devices in their home office. With AV Access HDEX60-DM dual monitor HDMI KVM extender, users can extend two full HD HDMI signals, along with USB 2.0, up to 60m/197ft simultaneously.”
AV Access HDEX60-DM dual monitor KVM extender allows users to extend two full HD HDMI signals and USB 2.0 up to 60m/197ft over a single Cat cable. It provides users with the ability to expand their screen real estate and optimize productivity, making it perfect for extending desktops, workstations, gaming PCs, and more.

AV Access, a leading provider of Pro AV and AV over IP solutions, recently expanded its KVM extender portfolio with the introduction of the HDEX60-DM 1080P HDMI extender. This innovative extender features a dual HDMI design, allowing users to extend two HDMI signals and USB 2.0 up to 60m/197ft over a single Cat cable. It is the perfect solution for extending desktops, workstations, gaming PCs, and more.

Innovative Dual HDMI Design

“Nowadays, an increasing number of people working from home tend to place their host PCs in their basement or equipment room for better centralized management, and they need to control one of the PCs remotely with two monitors and one set of USB peripherals in their personal home office or home studio, like 30m/100ft away. Our HDEX60-DM dual monitor HDMI extender is specially designed for them,” explained Bill Liao, CTO at AV Access.

Built-in USB 2.0 Hub

Designed with 4x USB 2.0 device port on the receiver, the HDMI KVM extender allows users to extend mouse, keyboard, printer, scanner or other USB 2.0 devices up to 60m/197ft. Two of the USB ports support 5V/1A higher current output, so users can easily connect high-power USB devices, such as USB camera or USB hard disk.

Besides, the HDEX60-DM HDMI extender is plug-n-play and works with all operating systems, including Windows 10/8/7/XP, Mac OS and Linux. It also features one-way PoC and ultra-slim appearance; users can almost place it everywhere in their house.

“Now HDEX60-DM is priced at only $199.99, available on our official site. It is a must-have gadget for extending your workstation or game console,” added Bill.

About AV Access

AV Access is the world’s professional manufacturer of advanced Pro AV and AV over IP products, which include extenders, splitters, switchers, matrixes, AV over IP codecs, etc. Since establishment, it has long been our mission to offer ultimate audiovisual experience to the masses by delivering quality-assured and well-designed AV products at honest pricing. We will continue to develop more innovative products and solutions in the fields of smart home, corporate, education, retail, entertainment, health care, etc. Strong R&D, powerful supply chain and excellent management team make AV Access be qualified as your faithful partner! Learn more by visiting www.avaccess.com.

Media Contact
Company Name: Actions Global (US) Inc
Contact Person: Shane Jiang
Email: Send Email
Phone: +1-866-629-3923
Address:100 N HOWARD ST STE R
City: City of Spokane
State: Washington 99201
Country: United States
Website: https://www.avaccess.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AV Access Launches New Dual Monitor KVM Extender for Enhanced Home Office and Gaming Experience

Community-Acquired Bacterial Pneumonia Market to Witness Growth by 2032, Estimates DelveInsight | Johnson & Johnson, Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharma

“Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the 7MM.

“Community-Acquired Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Community-Acquired Bacterial Pneumonia, historical and forecasted epidemiology as well as the Community-Acquired Bacterial Pneumonia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Community-Acquired Bacterial Pneumonia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Community-Acquired Bacterial Pneumonia Market Forecast

 

Some of the key facts of the Community-Acquired Bacterial Pneumonia Market Report: 

  • The Community-Acquired Bacterial Pneumonia market size was valued USD 2,616 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • CAP continues to be a major source of morbidity and mortality in the US, affecting 649 to 847 persons per 100,000 people and leading to over 1.6 million hospital admissions annually. More than 5 million new cases of CAP are diagnosed each year in the United States; 80% of these cases receive outpatient care with a death rate of less than 1%, and 20% receive inpatient care with a mortality rate of 12% to 40% (Sattar & Sharma, 2021)
  • Males had a greater incidence of CAP than females did (15.56; 95% CI, 13.90e17.43) versus 9.11 (7.87e10.55) per 10,000 people; p 0.0001. Males had greater incidence rates than females did (p 0.0001), and they rose with age
  • DelveInsight calculated that there were 6,886,685 incident instances of community-acquired bacterial pneumonia (CABP) in the 7MM people
  • Germany had the most Community-Acquired Bacterial Pneumonia (CABP) incident instances among the EU5 nations, with 568,953 cases in 2019
  • Key Community-Acquired Bacterial Pneumonia Companies: Paratek Pharmaceuticals, Forest Laboratories, Melinta Therapeutics, Inc., Chia Tai Tianqing Pharma, Nabriva Therapeutics, Biotest, ACM, AstraZeneca, Eagle Pharma, Cubist Pharma, Johnson & Johnson, Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, Basilea Pharmaceutica, and others
  • Key Community-Acquired Bacterial Pneumonia Therapies: Omadacycline, Ceftaroline, Delafloxacin, Faropenem, lefamulin, Omadacycline, BT086, Nafithromycin, Ceftaroline fosamil, tigecycline, CAL02, daptomycin, Levofloxacin, and others
  • The Community-Acquired Bacterial Pneumonia epidemiology based on gender analyzed that Male ratio is more compare to Female ratio in the case of Community-Acquired Bacterial Pneumonia (CABP)
  • The Community-Acquired Bacterial Pneumonia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Community-Acquired Bacterial Pneumonia pipeline products will significantly revolutionize the Community-Acquired Bacterial Pneumonia market dynamics.

 

Community-Acquired Bacterial Pneumonia Overview

Community-acquired bacterial pneumonia (CABP) is a frequent, severe lung parenchymal infection.It is a significant factor in adult mortality. One of the most common respiratory ailments among the several infections that might lead to sepsis is this one.

 

Get a Free sample for the Community-Acquired Bacterial Pneumonia Market Report 

https://www.delveinsight.com/report-store/community-acquired-bacterial-pneumonia-cabp-market

 

Community-Acquired Bacterial Pneumonia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Community-Acquired Bacterial Pneumonia Epidemiology Segmentation:

The Community-Acquired Bacterial Pneumonia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Community-Acquired Bacterial Pneumonia
  • Prevalent Cases of Community-Acquired Bacterial Pneumonia by severity
  • Gender-specific Prevalence of Community-Acquired Bacterial Pneumonia
  • Diagnosed Cases of Episodic and Chronic Community-Acquired Bacterial Pneumonia

 

Download the report to understand which factors are driving Community-Acquired Bacterial Pneumonia epidemiology trends @ Community-Acquired Bacterial Pneumonia Epidemiology Forecast

 

Community-Acquired Bacterial Pneumonia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Community-Acquired Bacterial Pneumonia market or expected to get launched during the study period. The analysis covers Community-Acquired Bacterial Pneumonia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Community-Acquired Bacterial Pneumonia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Community-Acquired Bacterial Pneumonia Therapies and Key Companies

  • Omadacycline: Paratek Pharmaceuticals
  • Ceftaroline: Forest Laboratories
  • Delafloxacin: Melinta Therapeutics, Inc.
  • Faropenem: Chia Tai Tianqing Pharma
  • lefamulin: Nabriva Therapeutics
  • Omadacycline: Paratek Pharma
  • BT086: Biotest
  • Nafithromycin: ACM
  • Ceftaroline fosamil: AstraZeneca
  • tigecycline: Pfizer
  • CAL02: Eagle Pharma
  • daptomycin: Cubist Pharma
  • Levofloxacin: Johnson & Johnson

 

Discover more about therapies set to grab major Community-Acquired Bacterial Pneumonia market share @ Community-Acquired Bacterial Pneumonia Treatment Market

 

Scope of the Community-Acquired Bacterial Pneumonia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Community-Acquired Bacterial Pneumonia Companies: Paratek Pharmaceuticals, Forest Laboratories, Melinta Therapeutics, Inc., Chia Tai Tianqing Pharma, Nabriva Therapeutics, Biotest, ACM, AstraZeneca, Eagle Pharma, Cubist Pharma, Johnson & Johnson, Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, Basilea Pharmaceutica, and others
  • Key Community-Acquired Bacterial Pneumonia Therapies: Omadacycline, Ceftaroline, Delafloxacin, Faropenem, lefamulin, Omadacycline, BT086, Nafithromycin, Ceftaroline fosamil, tigecycline, CAL02, daptomycin, Levofloxacin, and others
  • Community-Acquired Bacterial Pneumonia Therapeutic Assessment: Community-Acquired Bacterial Pneumonia current marketed and Community-Acquired Bacterial Pneumonia emerging therapies
  • Community-Acquired Bacterial Pneumonia Market Dynamics: Community-Acquired Bacterial Pneumonia market drivers and Community-Acquired Bacterial Pneumonia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Community-Acquired Bacterial Pneumonia Unmet Needs, KOL’s views, Analyst’s views, Community-Acquired Bacterial Pneumonia Market Access and Reimbursement 

 

To know more about Community-Acquired Bacterial Pneumonia companies working in the treatment market, visit @ Community-Acquired Bacterial Pneumonia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Community-Acquired Bacterial Pneumonia Market Report Introduction

2. Executive Summary for Community-Acquired Bacterial Pneumonia

3. SWOT analysis of Community-Acquired Bacterial Pneumonia

4. Community-Acquired Bacterial Pneumonia Patient Share (%) Overview at a Glance

5. Community-Acquired Bacterial Pneumonia Market Overview at a Glance

6. Community-Acquired Bacterial Pneumonia Disease Background and Overview

7. Community-Acquired Bacterial Pneumonia Epidemiology and Patient Population

8. Country-Specific Patient Population of Community-Acquired Bacterial Pneumonia 

9. Community-Acquired Bacterial Pneumonia Current Treatment and Medical Practices

10. Community-Acquired Bacterial Pneumonia Unmet Needs

11. Community-Acquired Bacterial Pneumonia Emerging Therapies

12. Community-Acquired Bacterial Pneumonia Market Outlook

13. Country-Wise Community-Acquired Bacterial Pneumonia Market Analysis (2019–2032)

14. Community-Acquired Bacterial Pneumonia Market Access and Reimbursement of Therapies

15. Community-Acquired Bacterial Pneumonia Market Drivers

16. Community-Acquired Bacterial Pneumonia Market Barriers

17.  Community-Acquired Bacterial Pneumonia Appendix

18. Community-Acquired Bacterial Pneumonia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Community-Acquired Bacterial Pneumonia Market to Witness Growth by 2032, Estimates DelveInsight | Johnson & Johnson, Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharma

KTGY Announces East Coast Office Move to Washington, D.C.’s Golden Triangle

“KTGY’s East Coast Office Relocating to the Heart of Washington, D.C.: Making Space for Collaboration”

WASHINGTON, D.C. – KTGY, a Great Places to Work certified design firm focused on architecture, branding, interiors and planning, has moved its East Coast office from Tysons, Virginia, to Washington, D.C.

Located in the Alexander Court development in D.C.’s Golden Triangle (2001 K St NW, South Tower, Suite 200), the new 15,000-square-foot office supports a steady course of national growth for KTGY. Founded in 1991, the firm expanded to Tysons, Virginia, in 2010. The move marks an opportunity to access some of the country’s leading industry organizations while continuing to deliver top-tier service to its clients, partners and collaborators.

The design of the new space, curated by KTGY’s interior design studio, emphasizes collaboration and nods to the firm’s commitment to sustainability. It will also welcome members of the interior design team focused on residential developments, allowing clients and team members to benefit from a wide range of expertise under one roof.

Ben Kasdan, principal, KTGY, says of the new office: “Since coming to Tysons in 2019, I’ve had the chance to work with amazing people on groundbreaking designs. Moving the office to the heart of downtown Washington, D.C. will inspire us to continue designing high-quality and sustainable spaces in the DMV region and throughout the East Coast.”

Proximity to professional organizations, a closer relationship with industry partners, and access to D.C.’s pool of international talent make up the bulk of what the firm sees as an investment in collaborative opportunities and innovation. The office is fully occupied and serves multifamily developers and for-sale builders while acting as a base for growth in East Coast markets.

For more information about the office design, please click here. 

About KTGY

Founded in 1991, KTGY is an award-winning design firm partnering with clients to deliver world-class architecture, branding, interiors and planning. Our firm and our work are guided by a continuous focus on innovation, creativity, collaboration, and a deep commitment we have towards making a positive impact on people and their communities. We use storytelling and design to envision and enliven spaces that transform people’s experiences.

Visit www.ktgy.com.

Media Contact
Company Name: KTGY
Contact Person: Brianne Wagner, Director, Demand Marketing
Email: Send Email
Phone: 18884565849
Address:17911 Von Karman Avenue Suite 200
City: Irvine
State: CA
Country: United States
Website: http://ktgy.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: KTGY Announces East Coast Office Move to Washington, D.C.’s Golden Triangle

SkillFusion Launches First-Of-Its-Kind Skill Enhancement and Certification Program Powering the Future of EV Infrastructure Demand

The EV Charger Diagnostic Technician Credentialing Program is designed to help professionals with limited or no prior experience unlock new career opportunities nationwide.

Detroit, MI – SkillFusion, a cutting-edge software platform for electric vehicle service equipment (EVSE) operations and maintenance (O&M) providers, has announced the launch of its EVSE Diagnostic Technician (EDT) Credentialing Program. This industry-first program provides non-electricians with the needed skills and certifications to carry out specific technical work on electric vehicle (EV) chargers, such as servicing communication and networking systems.

As stated in the Bipartisan Infrastructure Law (BIL), licensed electricians responsible for installing and maintaining the National Electric Vehicle Infrastructure (NEVI)-funded infrastructure must hold continuing education credit. SkillFusion’s EDT program offers a unique credential for non-electrical professionals to maintain and service EVSEs.

“As the NEVI program aims to build a widespread network of 500,000 EV chargers throughout the United States, the need for workers to not only install but maintain this infrastructure becomes critical,” said Elaina Farnsworth, Co-founder and CEO of SkillFusion. “SkillFusion’s EDT Credential ensures that EVSE maintenance and service work is being completed safely by certified technicians every time. ”

SkillFusion’s groundbreaking approach provides charger-agnostic skill enhancement and certification covering the full spectrum of skills needed to support EV charger operations, including technical support, networking and communications, cybersecurity, monthly O&M, and more. As workers complete their certification, they are placed within SkillFusion’s proprietary database of certified technicians—both for electrical and non-electrical workers—which allows EVSE O&M providers the ability to access a skilled labor pool to fulfill service obligations—unlocking unlimited job potential for those who have completed the EDT program.

“Not every service job will require a licensed electrician. SkillFusion’s training will provide the sector with a pipeline of certified technicians with a broader range of skills, critical to the operations and maintenance of the EV charging industry,” said Farnsworth. “Not only are we fusing this talent pool with endless opportunities but we supporting the industry’s goal to reduce charger downtime and increase charger reliability across the country.”

SkillFusion’s EDT program is now live and accepting enrollment. Individuals interested in enrolling in SkillFusion’s EDT credentialing program, can visit skillfusion.com for more information. The cost to enroll is $350 and includes 10 hours of training over the course of nine self-paced, on-demand training modules through SkillFusion’s MicroTraX platform.

This launch of the EDT program follows the awarding of $1.5 million to Ride and Drive Electric, a partnership projects which includes SkillFusion, through the Bipartisan Infrastructure Law (BIL). This project will develop a new EVSE Service Provider pre-apprenticeship program, complementing existing training. Graduates will be prepared to conduct assessments of EVSEs and address any non-electrical and programming issue and help ensure more reliable charging experiences for EV drivers.

About SkillFusion

SkillFusion is a first-of-its-kind approach to providing electric vehicle operations and maintenance (O&M) service providers with access to a nation-wide credentialed talent pool for electric vehicle service equipment (EVSE) O&M obligations. Through the company’s cross-sector training platform, SkillFusion is developing the largest talent pipeline of certified electrician and non-electrician workers available to EVSE O&M service providers with the mission to minimize charging infrastructure downtime and increase the reliability of the charging network. The platform will increase availability of certified EVSE workers ensuring that service providers have flawless accessibility to the right trained service technician for every job, every single time. To learn more about SkillFusion, visit www.SkillFusion.com.

 

Media Contact
Company Name: SkillFusion
Contact Person: Caleb Harper
Email: Send Email
Country: United States
Website: https://skillfusion.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: SkillFusion Launches First-Of-Its-Kind Skill Enhancement and Certification Program Powering the Future of EV Infrastructure Demand